What Buffering Capacity Does the Amine-Diol System Provide in Parenteral pH Adjustment?

The preparation of parenteral formulations containing 3-amino-1,2-propanediol requires strict control of solution pH prior to terminal sterilisation. The compound exhibits a measured pKa of approximately 8.8 for the primary amine moiety, which places the primary buffering action within the pH 7.8–9.8 range. In practice, this buffering capacity is exploited in parenteral systems where conventional phosphate or citrate buffers are pharmacologically unsuitable due to ion incompatibility or precipitation risk. A typical compounding sequence involves dissolving the monomer at 20–25 g/L in Water for Injection (WFI) pre-cooled to 15–20 °C, followed by pH adjustment with dilute hydrochloric acid (0.1 N HCl) to the target formulation pH. Dissolution requires continuous low-shear agitation at 100–150 rpm using an overhead stirrer fitted with a PTFE-coated blade; total dissolution time under these conditions ranges from 8–15 minutes depending on particle size distribution of the crystalline input. The resulting solution contributes a measurable osmolality increase: each 10 g/L addition elevates osmolality by approximately 110 mOsm/kg, as verified using vapour pressure osmometry per USP ⟨785⟩ criteria. The dissolution process itself is mildly endothermic. Temperature monitoring during large-scale batch preparation indicates a drop of 3–5 °C in solution temperature upon complete dissolution at the above concentration. Terminal sterilisation by autoclaving at 121 ± 1 °C for 15 minutes (saturated steam, F0 ≥ 12 minutes) does not induce measurable degradation when the solution pH is maintained between 5.5–8.0. Degradation products detected via HPLC-ELSD in accordance with Ph. Eur. 2.2.36 after autoclaving within this pH window remain below the 0.10 % individual impurity threshold. Below pH 5.0, the risk of intramolecular dehydration increases, producing azetidine intermediates detectable as late-eluting peaks in chromatographic profiles. Above pH 9.5, oxidative discoloration over hold times exceeding 24 hours at 25 °C becomes visible as a pale yellow hue with absorbance increase at 420 nm. These boundary conditions define the operating envelope for injectable product development. The terminal dosage form must also satisfy particulate matter requirements under USP ⟨788⟩ and bacterial endotoxin limits under USP ⟨85⟩; the raw material itself is tested for endotoxin content with acceptance at ≤ 0.50 EU/mg for parenteral-grade applications.

For regulatory submissions in injectable pathways, the raw material monograph alignment follows Ph. Eur. 2.2.20 for pH electrode calibration verification and ICH Q8(R2) for design-space definition. The compound has been evaluated for compatibility with common parenteral container systems: Type I borosilicate glass per USP ⟨660⟩ and cyclic olefin copolymer (COC) syringes show no detectable leachables above the analytical evaluation threshold after 24 months at 40 ± 2 °C and 25 ± 5 % RH. Rubber stopper compatibility testing per ICH Q1A(R2) confirms no meaningful sorption of the active species into halobutyl rubber formulations. The principal incompatibility in injectable compounding arises from the presence of trace metal ions, particularly Fe³⁺ and Cu²⁺, which catalyse oxidative degradation. Chelating water treatment is therefore mandatory in WFI systems used for dissolution; stainless steel contact surfaces in mixing vessels and transfer lines should be passivated to ASTM A967 specifications to minimise metal ion release.

The preparation of parenteral formulations containing 3-amino-1,2-propanediol requires strict control of solution pH prior to terminal sterilisation. The compound exhibits a measured pKa of approximately 8.8 for the primary amine moiety, placing primary buffering action within the pH 7.8–9.8 range. Compounding dissolves the material at 20–25 g/L in WFI pre-cooled to 15–20 °C, with pH adjustment using 0.1 N HCl. Terminal sterilisation at 121 ± 1 °C for 15 minutes (F0 ≥ 12 minutes) does not induce measurable degradation when pH is held between 5.5–8.0. Degradation products remain below 0.10 % individual impurity threshold per HPLC-ELSD analysis under Ph. Eur. 2.2.36.

Radiopharmaceutical Kit Preparation and Ligand Stabilisation

In radiopharmaceutical preparation, 3-amino-1,2-propanediol functions as a ternary ligand component and post-labelling stabiliser in certain technetium-99m diagnostic kits. The amine-diol motif coordinates the technetium core through nitrogen and oxygen donor atoms, displacing weakly bound water molecules from the coordination sphere and suppressing radiochemical degradation. Kit preparation involves lyophilisation of a formulation containing the ligand at 2.0–5.0 mg/vial alongside the active chelator and ancillary excipients. The lyophilisation cycle is conducted in GMP-grade freeze dryers equipped with shelf temperature control accurate to ± 0.5 °C and vacuum control to ± 5 mTorr. Primary drying proceeds at shelf temperature −25 ± 1 °C under vacuum below 100 mTorr (approximately 13.3 Pa) for 18–22 hours. Secondary drying raises the shelf temperature to 35 ± 1 °C for 4–6 hours, reducing residual moisture to below 1.0 % w/w. Stopper closure occurs under partial nitrogen atmosphere at 500–600 mbar absolute pressure. The moisture limit is operationally critical because residual water accelerates radiolytic degradation of the lyophilised cake upon reconstitution with sodium pertechnetate solution. Reconstituted kits are tested for radiochemical purity (RCP) by instant thin-layer chromatography (ITLC-SG) using methyl ethyl ketone and normal saline as dual solvent systems, with acceptance criterion RCP ≥ 90.0 % at 15 minutes post-reconstitution. Batch release data from production-scale lyophilisation loads indicate moisture variability of ± 0.3 % w/w across a 12-shelf configuration, indicating satisfactory thermal uniformity across the lyophiliser platen area.

The bulk material requires storage in double polyethylene liners within fibre drums under nitrogen blanket. Bulk storage at 20–25 °C and 35–45 % RH maintains assay ≥ 99.0 % for 24 months when protected from atmospheric moisture ingress. Uncontrolled exposure to ambient air at 50–60 % RH for periods exceeding 36 hours results in moisture uptake exceeding 3.0 % w/w, with corresponding reduction in lyophilisation performance. The principal incompatibility in radiopharmaceutical kit formulation arises from trace transition metal ions that compete for coordination sites. WFI systems employing reverse osmosis followed by deionisation to resistivity 18.2 MΩ·cm at 25 °C are specified. Passivation of all stainless steel contact surfaces to ASTM A967 is required before initial use and after any mechanical polishing operation.

Direct compression of pharmaceutical tablets containing 3-amino-1,2-propanediol as a formulation component is constrained by the hygroscopic nature and moderately low melting point of the compound. Bulk material solidifies from melt as waxy, low-density flakes with a tapped density ranging from 0.45–0.60 g/cm³. Milling through a FitzMill equipped with a 0.020-inch round-hole screen and knives forward at 1,200 rpm yields a free-flowing powder with D90 below 250 µm. The milled material exhibits a Carr Index in the range 18–25 %, indicating fair flowability suitable for gravity-assisted die feed on rotary tablet presses operating at turret speeds up to 45 rpm on a 16-station press. Granulation is required when the compound exceeds 40 % w/w of total tablet weight. Below this threshold, direct compression with microcrystalline cellulose (MCC) type PH102 and crospovidone at 2–5 % w/w as disintegrant achieves acceptable tablet hardness of 50–80 N without capping or lamination defects. The primary failure mode observed on production lines is edge chipping when compression force exceeds 12 kN and the tablet formulation lacks adequate plastic deformation capacity. Moisture uptake during direct compression at relative humidity above 60 % leads to punch face adhesion and weight variability exceeding ± 3.0 % RSD within 30 minutes of continuous operation. Dehumidified press rooms maintained at 35–45 % RH and 21 ± 2 °C are specified. Tablet tensile strength testing per USP ⟨1217⟩ provides a quality metric; formulations containing this compound typically display tensile strength in the 1.0–2.5 MPa range at solid fraction 0.85–0.90. Dissolution testing in 0.1 N HCl at 37 ± 0.5 °C with USP Apparatus II (paddle) at 50 rpm shows complete release within 15–30 minutes for immediate-release formulations. Tablet content uniformity per USP ⟨905⟩ must demonstrate acceptance value (AV) ≤ 15 for the first stage of testing.

The compatibility of 3-amino-1,2-propanediol with common tablet excipients has been assessed through binary mixture stability studies at accelerated conditions. Co-milling with lactose monohydrate at 90/10 w/w ratio produces no detectable Maillard reaction products after storage for 6 months at 40 °C and 75 % RH, as confirmed by HPLC analysis for coloured by-products. However, combination with mannitol at similar ratios shows increased moisture uptake and caking behaviour when exposed to ambient humidity above 55 % RH. Crospovidone and croscarmellose sodium demonstrate no chemical incompatibility with the compound under dry blending conditions; both disintegrants perform equivalently in disintegration time testing per USP ⟨701⟩, achieving tablet disintegration within 3–5 minutes at 37 °C in simulated gastric fluid.

High-Shear Granulation Endpoint Parameters in Aqueous Binder Systems

Wet granulation of 3-amino-1,2-propanediol-containing formulations employs aqueous binder solutions prepared at concentrations between 5–15 % w/w of polyvinylpyrrolidone (PVP K30) or hydroxypropyl methylcellulose (HPMC E5). The compound's high aqueous solubility — exceeding 1,000 g/L at 25 °C — complicates granulation endpoint control because partial dissolution during liquid addition modifies binder viscosity and granule nucleation behaviour. Granulation in a high-shear mixer with bowl capacity of 75 L proceeds with impeller speed 250–350 rpm and chopper speed 1,500–2,000 rpm. Liquid addition rate is controlled at 200–400 g/min through a peristaltic pump fitted with spray nozzle positioned 15–20 cm above the powder bed. The endpoint is confirmed via impeller torque measurement, targeting a plateau value corresponding to granule median diameter of 250–450 µm by sieve analysis per USP ⟨786⟩. Overt granulation manifests as torque spikes exceeding 120 % of baseline, with concomitant formation of over-wet, paste-like agglomerates that resist subsequent drying and prolong downstream milling operations. The granulate is dried in a fluid bed dryer with inlet air temperature 55–65 °C and air velocity 0.8–1.2 m/s, achieving residual moisture below 2.0 % w/w measured by Karl Fischer titration with oven coupling at 110 °C. Drying time correlates inversely with granule density: batches granulated to endpoint D50 of 350 µm dry within 45–60 minutes, while over-granulated batches with D50 above 600 µm require 120–180 minutes under identical conditions. This asymmetric drying behaviour serves as a process signature distinguishing acceptable from non-conforming granulation batches in routine manufacturing.

Granule hardness and porosity measurements further characterise the process. Granules produced under controlled endpoint conditions display friability below 1.0 % as determined by the rotating drum method at 25 rpm for 100 revolutions. The uniaxial compaction profile of the dried granulate demonstrates Heckel yield pressure values of 250–350 MPa, indicating intermediate plastic deformation capacity suitable for downstream tableting. The principal operational limit concerns binder solution preparation: PVP K30 solutions should be hydrated for a minimum of 30 minutes before addition to the granulation bowl to ensure homogeneous viscosity; incomplete hydration leads to localised binder-rich zones within the granulate, producing tablets with variable dissolution profiles and increased weight variability during compression.

When Capsule Filling Operates Below RH 45% to Maintain Bulk Flow

Hard gelatin capsule filling of formulations containing 3-amino-1,2-propanediol is performed on automatic dosator-nozzle or tamping-pin machines. The operational boundary is defined by ambient humidity rather than machine speed. At relative humidity above 50 %, the hygroscopic compound initiates moisture uptake that causes powder bed consolidation and erratic weight variation in size 0 capsules exceeding ± 5.0 % RSD. Conditions are therefore maintained at 35–45 % RH and 20–24 °C, with the powder hopper and dosing area enclosed in conditioned laminar flow. Dosator machines typically run at 75–100 % of nominal speed for this material class, with compression settings between 15–25 mm dosator pin depth and ejection force calibrated for powder plug densities of 0.65–0.80 g/cm³. Tamping-pin machines offer superior weight uniformity for this compound due to progressive densification across five tamping stations. Weight variability on tamping-pin equipment at 80 % of rated speed is documented as ± 1.5–2.5 % RSD, outperforming dosator systems at equivalent output. The primary operational failure is capsule shell softening caused by localised moisture transfer from the fill material. Gelatin capsule shells with moisture content of 13–16 % w/w per USP ⟨922⟩ capsular moisture absorb additional water when filled powder moisture exceeds 2.5 % w/w, leading to deformation at the cap-body junction and rejection at the inspection station. Pre-fill conditioning of the bulk powder in a desiccator at 25 °C and 25–30 % RH for 8–12 hours reduces feed moisture to below 1.5 % w/w, restoring flow characteristics and maintaining shell integrity throughout the encapsulation run.

The end product specification for capsule formulations includes dissolution testing per USP ⟨711⟩ with Apparatus I (basket) at 100 rpm in 900 mL of 0.1 N HCl at 37 ± 0.5 °C. Capsules containing the compound show release profiles that correlate with fill weight and granule porosity rather than with dissolution medium pH within the physiological range. The primary regulatory requirement for capsule products falls under ICH Q3D elemental impurities control, with particular attention to zinc and iron from equipment contact surfaces; analytical quantification is performed by ICP-MS per USP ⟨233⟩ with acceptance limits corresponding to the parenteral and oral permitted daily exposure limits defined in ICH Q3D Table 2.

Reaction stoichiometry in pharmaceutical intermediate synthesis involving 3-amino-1,2-propanediol requires precise control of molar ratios and temperature ramping to minimise by-product formation. The compound serves as a primary synthetic intermediate in the production of non-ionic iodinated X-ray contrast media, most notably iopamidol. The substance supplies the amine-diol backbone onto which triiodinated benzoic acid derivatives are condensed. The coupling reaction proceeds via amide bond formation using thionyl chloride (SOCl₂) as activating agent in dimethylacetamide (DMAc) at controlled temperatures between −5 °C and +5 °C. Molar stoichiometry is maintained at 1:1.05 amine-to-acyl chloride equivalent to compensate for moisture-induced hydrolysis losses. Reaction monitoring by HPLC with UV detection at 240 nm tracks disappearance of the starting amine. Typical isolated yields at production scale range from 75–85 % of theoretical, with the balance lost to by-product formation and work-up losses. The product is crystallised from a solvent mixture of isopropanol and deionised water in a 7:3 v/v ratio, yielding enantiomeric excess (ee) of ≥ 99.0 % when the chiral starting material is employed. Optical rotation is measured per Ph. Eur. 2.2.7, with specific rotation specifications defined for each enantiomeric form. Residual solvent analysis per ICH Q3C Option 1 confirms DMAc below 1,090 ppm and isopropanol below 5,000 ppm in the isolated material. The process is conducted in glass-lined reactors because the presence of free amine during acid chloride addition generates HCl vapour that accelerates corrosion of unlined stainless steel. Batch records from multi-hundred-kilogram campaigns indicate that moisture ingress during charging operations reduces yield by 8–12 % relative to campaigns conducted under nitrogen. This sensitivity mandates inert atmosphere transfer systems and inline moisture monitoring of solvent feeds.

The amide formation step is followed by hydrolysis of the intermediate ester and final purification through recrystallisation. The overall process from 3-amino-1,2-propanediol to iopamidol typically spans 5–7 synthetic steps at production scale, with cumulative yield from starting amine to final API in the range of 25–35 %. Process analytical technology (PAT) implementation includes in-line Raman spectroscopy for reaction endpoint determination, reducing the reliance on off-line HPLC turnaround time of 45–60 minutes. The primary quality risk in the synthetic pathway concerns chiral integrity during high-temperature distillation of intermediates; temperatures must not exceed 80 °C during solvent recovery to prevent racemisation at the stereogenic centre.

Oral liquid preparations incorporating 3-amino-1,2-propanediol require stability assessment under ICH Q1A(R2) conditions to establish shelf-life claims for aqueous solutions. The compound remains chemically stable in buffered aqueous media across the pH range 4.0–9.0 when stored at 25 ± 2 °C and 60 ± 5 % RH for 12 months. At extreme pH values outside this range, degradation accelerates: at pH 2.0, hydrolysis of the amine-diol bond is observed at a rate constant of approximately 0.021 day⁻¹ at 40 °C, corresponding to 10 % degradation in 5 days. At pH 12.0, oxidative degradation in the presence of dissolved oxygen produces an aminoketone derivative detectable by LC-MS at retention-time shift of +1.8 minutes relative to the parent compound. Formulation of oral solutions typically uses a citrate or phosphate buffer at 10–50 mM ionic strength, with tonicity adjustment by sodium chloride or sorbitol according to pharmacopoeial osmolality recommendations USP ⟨785⟩. Antimicrobial preservation is mandatory for multi-dose oral solutions; parabens (methyl paraben 0.18 % w/v, propyl paraben 0.02 % w/v) and potassium sorbate at 0.10–0.15 % w/v demonstrate compatibility when assayed over 24 months at 25 °C. The compound does not undergo significant photodegradation under ICH Q1B Option 2 exposure (visible light 1.2 million lux-hours, UV 200 W·h/m²), as confirmed by HPLC assay retention of 99.5 % relative to dark controls. The principal pharmaceutical incompatibility in liquid formulations is with reducing sugars such as glucose or fructose, which undergo Maillard reaction with the primary amine, producing brown discoloration and reducing assay by up to 15 % over 6 months at 40 °C. Sucrose is acceptable provided formulation pH remains below 7.0.

The terminal oral liquid product is filled into amber Type III soda-lime glass bottles or HDPE containers with child-resistant closures. In-use stability after opening is demonstrated for 28 days at 25 °C without significant assay loss, provided the product is stored with closure tightly secured. The viscosity of the final solution at concentrations up to 100 g/L remains below 10 mPa·s at 25 °C, as measured by rotational viscometry using a cone-plate geometry per USP ⟨912⟩. This low viscosity profile ensures uniform dose delivery from oral dosing syringes and minimises dosing error at the point of administration.

Do Amine-Diol Stabilisers Preserve Antigen Conformation During Freeze-Thaw Cycling?

Vaccine formulation studies have evaluated 3-amino-1,2-propanediol as a glass-forming stabiliser and cryoprotectant in subunit and live-attenuated preparations. The compound's dual hydroxyl and amine functionalities permit hydrogen bonding with protein surface residues and lipid envelope components, providing protection against ice crystal damage during freezing. Differential scanning calorimetry (DSC) at heating rate 10 °C/min indicates a glass transition temperature (Tg′) of the maximally freeze-concentrated solution at approximately −41 °C. This value situates the compound's protective behaviour between sucrose (Tg′ ≈ −32 °C) and sorbitol (Tg′ ≈ −43 °C). Formulation screening at protein concentration 0.5–2.0 mg/mL and stabiliser concentration 5–15 % w/v demonstrates retention of antigen potency above 80 % after 10 freeze-thaw cycles from −70 °C to +25 °C, as measured by ELISA titre in accordance with WHO Technical Report Series guidelines. The stabilisation mechanism is attributed to preferential exclusion from the protein surface, quantified by preferential interaction parameter values consistent with surface-tension increment measurements. Freeze-drying of stabilised vaccine formulations is performed in vials with fill depth not exceeding 10 mm, using a cycle that holds shelf temperature at −35 °C during primary drying and ramps to +30 °C over 6 hours for secondary drying. Final residual moisture below 1.0 % w/w is verified by Karl Fischer analysis per USP ⟨921⟩. The principal limitation in vaccine applications arises from the compound's reactivity with aldehyde-containing adjuvants and inactivation agents. Formaldehyde-treated antigens exhibit reduced potency recovery when 3-amino-1,2-propanediol is added prior to formaldehyde neutralisation, due to competitive Schiff base formation. Process sequencing must therefore separate inactivation and stabiliser addition steps by a minimum hold time of 2 hours at 4 °C.

The vaccine stabilisation pathway also involves considerations related to cold chain logistics and terminal product release. Bulk stabilised antigen solutions stored at 2–8 °C show potency retention ≥ 95 % for 12 months, with degradation kinetics following first-order dependence at a rate constant below 0.002 day⁻¹. The presence of the stabiliser modifies the shear sensitivity of antigen solutions during aseptic filtration; filter flux rates through 0.22 µm PVDF membranes at 1.0–1.5 bar differential pressure remain linear up to filtration volumes of 500 L/m², indicating no significant membrane fouling. Long-term storage of lyophilised vaccine formulations at 5 ± 3 °C maintains potency above 90 % for 24 months, as supported by real-time stability data rather than accelerated condition extrapolation alone. The primary equipment requirement is a lyophiliser configured for automatic pressure rise testing to confirm chamber integrity before each sublimation cycle, with leak rate acceptance limit not exceeding 0.5 mbar·L/s as measured by vacuum decay method.